Irritable Bowel Syndrome Research Studies

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder. The most common symptoms of IBS are abdominal pain or discomfort, often reported as cramping, along with diarrhea, constipation, or both. IBS is diagnosed when a person has abdominal pain or discomfort at least three times per month for the last three months without other disease or injury that could explain the pain. The pain or discomfort of IBS may occur with a change in stool frequency or consistency or may be relieved by a bowel movement. IBS is often classified into four subtypes based on a person’s usual stool consistency: 1) IBS with constipation (IBS-C), 2) IBS with diarrhea (IBS-D), 3) Mixed IBS (IBS-M), and 4) Unsubtyped IBS (IBS-U).

Enrolling: No

Principle Investigator: TBD

Primary Outcomes Measured: Lactase activity (µmol/min/g) will be assessed from small bowel biopsy specimens.

Secondary Outcomes Measured: 

1. Symptom severity will be assessed using the lactose assessment tool
2. The small intestinal microbiome will be assessed by 16S allele PCR sequencing and Shotgun Metagenomic Sequencing
3. Maldigestion status will be assessed by hydrogen breath test
4. The fecal microbiome will be assessed by 16S allele PCR sequencing and Shotgun Metagenomic Sequencing
   

Enrolling: No

Principle Investigator: TBD

Primary Outcomes Measured:

1. Early adverse life events
2. Prevalence of Post-traumatic Stress Disorder (PTSD)
3. Change in weekly number of complete spontaneous bowel movements
4. Change in abdominal pain

Secondary Outcomes Measured:

1. Presence of IBS or functional constipation
2. Existence and severity of psychological comorbidities
3. Health-related quality of life
4. Constipation-related symptoms
5. Constipation-related quality of life
   

Enrolling: No

Principle Investigator: TBD

Duration: 6 days, 3 visits

Primary Outcomes Measured:

1. Total fecal bile acids
2. Total fecal short chain fatty acids
3. Individual fecal short chain fatty acids
4. Fecal microbial population
5. Fecal inulin

Secondary Outcomes Measured:

1. Percent primary fecal bile acids
2. Stool characteristics
   

Enrolling: No
Principle Investigator: TBD
Primary Outcomes Measured:

1. Total and individual fecal bile acid excretion
2. Total fecal excretion of short chain fatty acids
3. Fecal microbial population and community from stool

Secondary Outcomes Measured:

1. Fecal excretion of individual short chain fatty acids
2. Stool characteristics